+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Urinary Incontinence Treatment Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • ID: 5012648
  • Report
  • April 2022
  • Region: Global
  • 122 Pages
  • Mordor Intelligence

The urinary incontinence treatment devices market was valued USD 3392.92 million in 2021 and is expected to grow at a CAGR of 6.6% during the forecast period.



In the initial days of the COVID-19 pandemic 2020, several countries were in lockdown. They suspended trade with other countries and implemented travel restrictions, leading to the decline in diagnosis and surgical procedures in the first half of 2020.



According to the study published in the British Journal of Surgery, in May 2020, based on a 12-week period of peak disruption to hospital services due to COVID-19, around 28.4 million elective surgeries worldwide were canceled or postponed in 2020. In addition, more than 580,000 planned surgeries in India were canceled or delayed because of the COVID-19 pandemic, according to a study conducted by an international consortium in May 2020.



The major factor attributing to the growth of the market is the rising prevalence of urinary incontinence (UI). Numerous factors such as urinary tract infection, weakening of pelvic floor muscles and urethral sphincters, menopause, pregnancy, and childbirth and post radical prostatectomy surgery in men lead to the development of urinary incontinence symptoms. A study entitled “Prevalence of Urinary Incontinence among Young Healthy Females in Gujarat - A Cross Sectional Study” published in June 2021 concluded that, after the study period of 11 month from December 2017 to October2018, they found that, among the total population, the prevalence of UI was 71.85 % among young women and healthy of age between 18-25 years, 50.85% had stress, 9.16% had urge and 40 % of them had mixed type of urinary incontinence.



The article entitled 'Urinary Incontinence in Postmenopausal Women (2019)', published in National Center for Biotechnology Information (NCBI), it was found that there is a rise in the incidence of various diseases, such as Parkinson's disease, diabetes, multiple sclerosis etc., which may lead to increased prevalence of urinary incontinence in males and females. This is expected to increase demand for urinary incontinence treatment devices over the forecast period. Furthermore, rising demand for minimally invasive procedures and increasing technological advancements boost the market growth. These increasing research and development in the field of UI is creating awareness among people and opening opportunities for the studied market, which is expected to propel the studied market growth.



Moreover, the market players are adopting various strategies, such as product launches, developments, acquisitions, merges, and collaborations, to expand their product portfolio in the market studied, and is boosting the market growth. For instance, in November 2019, Renovia Inc. announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the next-generation leva Pelvic Digital Therapeutic which will be used for strengthening of pelvic floor muscles, also the treatment of stress, mixed and mild to moderate urgency urinary incontinence (UI) in women.



However, factors such as lack of awareness about devices and social stigma associated with the disease, and the risks and complications related to the procedures, are expected to impede market growth over the forecast period.



Key Market Trends


Urethral Slings Segment is Expected to Witness a Healthy Growth Rate Over the Forecast Period


The urethral slings segment is expected to witness growth as these are highly recommended for surgical treatment for the treatment of stress urinary incontinence.



A study entitled 'A Global Survey on the Impact of COVID-19 on Urological Services', published in August 2020, shows that during covid 19, the outpatient clinics for female urinary incontinence, benign prostatic hyperplasia, infertility, and sexual medicine, renal stone, benign scrotal conditions, and bladder stone were most affected among others. Besides, there was cut-down across various types of outpatient investigations and procedures during the pandemic in 2020. Particularly surgical procedures for female urinary incontinence, infertility, renal stones, and bladder stones had the highest rates of cut-down services. These somehow affected the growth of the segment negatively.



Urethral slings surgery is also known as mid-urethral sling surgery where the sling material used may be muscle, ligament, or tendon tissue taken from the woman or from an animal, such as a pig. It may also be composed of synthetic material, such as plastic that is compatible with body tissues or of absorbable polymer that disintegrates over time.



According to an article published in February 2021, entitled “Urinary Incontinence in Women Common, but Treatable”, urinary incontinence is the unconditional loss of urine, which can be a few drops of leakage to a full accident and almost 1 in 2 women over the age of 50 deal with the issues related to this urinary incontinence, also this article mentioned, more than 25 million Americans admit that they regularly face issues controlling their bladders. The rising prevalence of urinary incontinence among the women and the aging population is increasing the demand for urethral sling surgery.



Furthermore, quick recovery time of the procedures are increasing its demand among patient population. Apart from the low-risk rates and advantages of the sling procedures, the increasing demand for minimally invasive surgeries is also boosting the segment growth.



Boston Scientific launched a redesign of its mesh sling system in February 2019, which is a surgical implant for stress urinary incontinence in male patients and the surgical mesh is also implanted to support the urethra neck to correct stress urinary incontinence (SUI).



Moreover, the growing volume of urinary incontinence and cumulative research in the arena of urinary incontinence treatment adoptions are the major factors for the growth of the urethral slings segment.





North America is Expected to Hold a Significant Share in the Market Over the Forecast Period


The major driving factors attributing to the market growth in the North American region are increasing the prevalence of urinary incontinence (UI), the increasing geriatric population, and the increasing demand for minimally invasive surgeries in the region.



A revenue decline among the market players has been seen in the urology platform due to the COVID-19 outbreak. For instance, the interventional urology segment of Coloplast Corp. generated a negative organic growth (-7%) in the financial year 2019-20. The negative growth was mainly due to a decrease in sales of Altis single-incision slings and other products followed by cancellation of elective surgeries and procedures in the United States after the COVID-19 outbreak. The elective procedures outside of the United States were also postponed in several countries during the covid-19 outbreak.



The studied market has shown growth in the North American region despite the negative impact of the pandemic owing to other factors. As of July 2019, the Canadian geriatric population included 6,592,611 people, which accounted for 17.5% of the Canadian population, as per the Government of Canada’s statistics report. This proportion of senior citizens in Canada has been increasing with time. As aging increases the risk of bladder problems such as bladder control issues, and leakage or urinary incontinence, hence the increasing aging population is positively influencing the Canadian market for urinary incontinence treatment devices market.



As per the article published in Medscape in June 2021 on “What is the prevalence of urinary incontinence?”, it has been estimated that UI will affect 10-13 million people in the United States. Additionally, the cost of treatment of UI in the United States alone is USD 16.3 billion, 75% of which is spent on treatment of women. This increasing prevalence of UI in the United States is expected to propel the growth of the studied market.



Strategies adopted by major companies, such as research and development, mergers and acquisitions, and product launches to strengthen their market position is another driving factor for the growth of the studied market. In February 2020, Atlantic Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted over the counter (OTC) clearance to INNOVO, a non-invasive, clinically proven, and wearable device for the treatment of stress urinary incontinence (SUI) in adult females. Therefore, these afore-mentioned factors are expected to boost the urinary incontinence treatment devices market in the region over the forecast period.





Competitive Landscape


The urinary incontinence treatment devices market is moderately competitive. Some of the companies which are currently dominating the market are Boston Scientific Corporation, Becton, Dickinson and Company., Coloplast Corp, Promedon Group, A.M.I. GmbH, Johnson & Johnson, Zephyr Surgical Implants, Medtronic PLC, Caldera Medical Inc, Hollister Incorporated, Nipro Corporation, Karl Storz SE & Co. KG, B Braun Melsungen AG, Baxter International Inc, ConvaTec Group Plc.



Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support


This product will be delivered within 2 business days.
Note: Product cover images may vary from those shown

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Urinary Incontinence and Rise in Geriatric Population
4.2.2 Rise in Demand for Minimally Invasive Surgery and Product Development
4.3 Market Restraints
4.3.1 Lack of Awareness about Devices and Social Stigma Associated with the Disease
4.3.2 Risks and Complications from the Procedures
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Product
5.1.1 Urethral Slings
5.1.2 Electrical Stimulation Devices
5.1.3 Artificial Urinary Sphincters
5.1.4 Catheters and Others
5.2 By End-User
5.2.1 Hospitals
5.2.2 Ambulatory Surgical Centres
5.2.3 Other End-Users
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPANY PROFILES AND COMPETITIVE LANDSCAPE
6.1 Boston Scientific Corporation
6.2 BD
6.3 Colopast Group
6.4 PROMEDON GmbH
6.5 A.M.I. GmbH
6.6 Johnson & Johnson (Ethicon)
6.7 Zephyr Surgical Implants
6.8 Medtronic
6.9 Caldera Medical Inc.
6.10 Hollister Incorporated
6.11 KARL STORZ SE & Co. KG
6.12 B Braun Melsungen AG
6.13 ConvaTec Group PLC
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown

Loading
LOADING...

Loading
LOADING...